Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545858 | 0.71 | SMN1; SMN2 (0.59) | ALDH1A1TP53SMN1; SMN2MAPTLMNA | |
| SCHEMBL13545773 | 0.70 | KMT2A (0.72) | ALDH1A1TP53SMN1; SMN2MAPTLMNA | |
| SCHEMBL13545805 | 0.70 | LMNA (0.46) | ALDH1A1TP53SMN1; SMN2MAPTLMNA | |
| SCHEMBL18716697 | 0.65 | GHSR (0.76) | ALDH1A1GHSRKMT2A | |
| SCHEMBL13545811 | 0.65 | LMNA (0.57) | ALDH1A1SMN1; SMN2MAPTLMNANPC1 | |
| SCHEMBL12004580 | 0.65 | GHSR (1.00) | GHSRKMT2A | |
| SCHEMBL12004771 | 0.65 | GHSR (1.00) | GHSRKMT2A | |
| SCHEMBL12004577 | 0.65 | GHSR (1.00) | GHSRKMT2A | |
| SCHEMBL13545851 | 0.64 | ALDH1A1 (0.48) | ALDH1A1TP53SMN1; SMN2MAPTLMNA | |
| SCHEMBL12005633 | 0.63 | OPRM1 (0.56) | ALDH1A1GHSRSMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022530-A1 | TETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN | MERCK PATENT GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022530-A1 | TETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN | MERCK PATENT GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| WO-2008080455-A1 | TETRAHYDROBENZOISOXAZOLE - AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022530-A1 | TETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN | CCNB3, TUBB3, CCNB1 | ALDH1A1 2977/4885TP53 711/4885GHSR 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.